Since 2014, with the introduction of Direct Acting Antiviral agents (DAA's) the HCV landscape has dramatically changed and many patients have been treated since the introduction of these products. In many countries however, to date, treatment has been restricted to more severe patients. Furthermore in most of the countries a significant proportion of patients are still undiagnosed. This educational symposium will discuss some of the Health Economics aspects of treating HCV patients with DAA’s. Furthermore, experts in the field will present if and how disease eradication can become a reality and the different actions stakeholders can take to make disease eradication a realistic ambition.